好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Analysis of 48-Week Data from the EVIDENCE Study on MRI T2 Burden of Disease with Subcutaneously-Administered Interferon beta-1a 44 mcg Three-Times-Weekly Than with Interferon beta-1a 30 mcg Administered Intramuscularly Once-Weekly
MS and Related Diseases
(-)
094
Authors/Disclosures
Anthony Traboulsee, MD (University of British Columbia) Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Consortium of MS Centers. The institution of Dr. Traboulsee has received research support from MS Canada. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Workshop Chair with Consortium of MS Centers.
Luigi Lavorgna Luigi Lavorgna has nothing to disclose.
Ahmad M. Al-Sabbagh, MD (Avion Pharmaceuticals) Dr. Al-Sabbagh has nothing to disclose.
No disclosure on file
Randy Bennett (Serono Inc) No disclosure on file
Peter Chang No disclosure on file
Robert L. Glanzman, MD, FAAN (Advance Neuroscience Clinical Research) Dr. Glanzman has received personal compensation for serving as an employee of Clene Nanomedicine Inc. Dr. Glanzman has stock in Clene Nanomedicine Inc .
No disclosure on file
No disclosure on file